Apalutamide Added to NCCN Prostate Cancer Guidelines

March 12, 2018 – The NCCN now lists apalutamide as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). In treatment guidelines issued March 8, 2018, the NCCN included the next-generation androgen receptor inhibitor as a treatment option for patients with M0 disease, especially in those for whom PSA doubling time is ≤10 months. The FDA approved apalutamide in February 2018 for … (leggi tutto)